The organization has more than 500 technologies in development and oversees over 1,100 patents, focusing on biotech, medtech and digital health solutions advancing precision medicine.
“The idea is to identify all innovations and inventions from within our medical center and support the path to commercialize them domestically and globally,” said James Laur, chief intellectual property officer at Cedars-Sinai, in an April 16 news release.
A particularly successful Cedars-Sinai Technology Ventures spinoff is Prometheus Biosciences, the developer of a new therapeutic to treat inflammatory bowel disease. The health system’s venture fund had invested $40 million in the company, which was sold last June to Merck for nearly $11 billion, an estimated $800 million of which came back to Cedars-Sinai.
“It was the first such success at this scale seen in technology transfer offices around the world and validated our unique approach to bring new inventions to the market,” stated Nirdesh Gupta, PhD, managing director of Cedars-Sinai Technology Ventures and the Cedars-Sinai Accelerator.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
